JP6389884B2 - 癌を治療するための方法及び組成物 - Google Patents
癌を治療するための方法及び組成物 Download PDFInfo
- Publication number
- JP6389884B2 JP6389884B2 JP2016526034A JP2016526034A JP6389884B2 JP 6389884 B2 JP6389884 B2 JP 6389884B2 JP 2016526034 A JP2016526034 A JP 2016526034A JP 2016526034 A JP2016526034 A JP 2016526034A JP 6389884 B2 JP6389884 B2 JP 6389884B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- fli1
- group
- erg
- ews
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895308P | 2013-10-24 | 2013-10-24 | |
| US61/895,308 | 2013-10-24 | ||
| PCT/US2014/061418 WO2015061229A1 (en) | 2013-10-24 | 2014-10-20 | Methods and compositions for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534084A JP2016534084A (ja) | 2016-11-04 |
| JP2016534084A5 JP2016534084A5 (cg-RX-API-DMAC7.html) | 2017-11-16 |
| JP6389884B2 true JP6389884B2 (ja) | 2018-09-12 |
Family
ID=52993423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526034A Active JP6389884B2 (ja) | 2013-10-24 | 2014-10-20 | 癌を治療するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9511050B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3060207A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6389884B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160065986A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105848654B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014340398A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2927148A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL245281A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016004678A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016114498A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015061229A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| MX377618B (es) | 2012-04-12 | 2025-03-07 | Univ Georgetown | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. |
| JP6389884B2 (ja) * | 2013-10-24 | 2018-09-12 | ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ | 癌を治療するための方法及び組成物 |
| EP3204376B1 (en) | 2014-10-09 | 2023-04-19 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US9822122B2 (en) | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| SI3800189T1 (sl) | 2016-05-18 | 2023-11-30 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| US10613088B2 (en) * | 2016-06-12 | 2020-04-07 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| US10761081B2 (en) * | 2016-06-12 | 2020-09-01 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| MX395539B (es) | 2016-07-29 | 2025-03-25 | Oncternal Therapeutics Inc | Usos de compuestos de indolinona |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CA3054836A1 (en) * | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Detecting prostate cancer |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110845389A (zh) * | 2019-10-17 | 2020-02-28 | 袁健 | 一种新型i型拓扑异构酶抑制剂 |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| AU1648600A (en) * | 1998-12-04 | 2000-06-26 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| US7674778B2 (en) | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
| US20090217390A1 (en) | 2005-04-29 | 2009-08-27 | Fernando Lecanda Cordero | Non-human animal sarcoma model |
| EP2687206B1 (en) | 2006-12-29 | 2017-12-13 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| IN2009KN03959A (cg-RX-API-DMAC7.html) | 2007-04-20 | 2015-08-28 | Univ New York State Res Found | |
| US20130259927A1 (en) | 2012-04-02 | 2013-10-03 | Gradalis, Inc. | Ewing's Sarcoma Bifunctional shRNA Design |
| MX377618B (es) | 2012-04-12 | 2025-03-07 | Univ Georgetown | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. |
| JP6389884B2 (ja) * | 2013-10-24 | 2018-09-12 | ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ | 癌を治療するための方法及び組成物 |
-
2014
- 2014-10-20 JP JP2016526034A patent/JP6389884B2/ja active Active
- 2014-10-20 MX MX2016004678A patent/MX2016004678A/es unknown
- 2014-10-20 RU RU2016114498A patent/RU2016114498A/ru not_active Application Discontinuation
- 2014-10-20 WO PCT/US2014/061418 patent/WO2015061229A1/en not_active Ceased
- 2014-10-20 US US15/030,713 patent/US9511050B2/en active Active
- 2014-10-20 EP EP14855801.8A patent/EP3060207A4/en not_active Withdrawn
- 2014-10-20 KR KR1020167013692A patent/KR20160065986A/ko not_active Withdrawn
- 2014-10-20 CN CN201480071102.0A patent/CN105848654B/zh active Active
- 2014-10-20 CA CA2927148A patent/CA2927148A1/en not_active Abandoned
- 2014-10-20 AU AU2014340398A patent/AU2014340398A1/en not_active Abandoned
-
2016
- 2016-04-21 IL IL245281A patent/IL245281A0/en unknown
- 2016-11-30 US US15/365,794 patent/US20170157089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2927148A1 (en) | 2015-04-30 |
| CN105848654A (zh) | 2016-08-10 |
| CN105848654B (zh) | 2018-10-02 |
| EP3060207A1 (en) | 2016-08-31 |
| US20170157089A1 (en) | 2017-06-08 |
| MX2016004678A (es) | 2017-03-10 |
| RU2016114498A (ru) | 2017-11-29 |
| RU2016114498A3 (cg-RX-API-DMAC7.html) | 2018-08-13 |
| JP2016534084A (ja) | 2016-11-04 |
| IL245281A0 (en) | 2016-06-30 |
| AU2014340398A1 (en) | 2016-06-09 |
| EP3060207A4 (en) | 2017-04-12 |
| US20160263086A1 (en) | 2016-09-15 |
| KR20160065986A (ko) | 2016-06-09 |
| WO2015061229A1 (en) | 2015-04-30 |
| US9511050B2 (en) | 2016-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6389884B2 (ja) | 癌を治療するための方法及び組成物 | |
| JP6345301B2 (ja) | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 | |
| KR102375929B1 (ko) | 인돌린 유사체 및 이의 용도 | |
| AU2015328121B2 (en) | Indolinone compounds and uses thereof | |
| US11267817B2 (en) | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | |
| Zhao et al. | Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity | |
| CA3224123A1 (en) | Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2) | |
| HK1242313B (zh) | 用於治疗尤文肉瘤家族肿瘤的方法和组合物 | |
| HK1207368B (en) | Compounds and compositions for treating ewings sarcoma family of tumors | |
| HK1242313A1 (en) | Methods and compositions for treating ewing's sarcoma family of tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160628 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20160628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171003 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171003 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180626 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180704 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180820 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6389884 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |